Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

130 ta ish

Ish: Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

  1. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

    Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar +2

    Sharh maqola20183 iqtibos
    ABI

  2. F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic That Targets Both Murine and Human Ovarian Tumor Endothelial Cells <i>In vivo</i>

    Ira Winer, Shouyan Wang, Youg-Eun Koo Lee +6

    Maqola20102 iqtibos
    ABI

  3. Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines

    Shi Du, Hui Xiong, Cheng Xu +2

    Maqola20192 iqtibos
    ABI

  4. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models

    Qiaohong Wang, Jingze Gao, Wen Di +1

    Maqola20202 iqtibos
    ABI

  5. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

    Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum +2

    Sharh maqola20212 iqtibos
    ABI

  6. Angiopoietin inhibitors: A review on targeting tumor angiogenesis

    Parmar Digna, Madhavi Apte

    Sharh maqola20212 iqtibos
    ABI

  7. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

    Elizabeth Allen, Arnaud Jabouille, Lee B. Rivera +8

    Maqola20172 iqtibos
    ABI

  8. MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis

    Lisa M. Coussens, Christopher L. Tinkle, Douglas Hanahan +1

    Maqola20002 iqtibos
    ABI

  9. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma

    Thanh-Nhan Nguyen-Pham, Sung‐Hoon Jung, Manh-Cuong Vo +7

    Maqola20152 iqtibos
    ABI

  10. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations

    Р. В. Холоденко, Daniel Kalinovsky, Igor I. Doronin +2

    Sharh maqola20192 iqtibos
    ABI

  11. Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

    Ruixue Zhang, Ho Lun Wong, Hui Xue +2

    Sharh maqola20162 iqtibos
    ABI

  12. Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

    Rakesh K. Jain

    Sharh maqola20132 iqtibos
    ABI

  13. Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling

    Raquel Batlle, Eva Andrés, Lorena González +5

    Maqola20192 iqtibos
    ABI

  14. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    James A. Bonner, Paul M. Harari, J. Giralt +14

    Maqola20062 iqtibos
    ABI

  15. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo +17

    Maqola20182 iqtibos
    ABI

  16. A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

    Magnus Lindskog, Anna Laurell, Anders Kjellman +17

    Maqola20202 iqtibos
    ABI

  17. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa1 iqtibos
    ABI